Physician
Oncology
Dr. Anibal Drelichman, MD
|
|
Give Review
Anibal Drelichman practices Oncology. He graduated from Wayne State University School of Medicine. Wayne State University School of Medicine has a rank of 63 in research and a 85 in primary care Anibal Drelichman is a published physician as well. He has 24 publications published. The latest was: Bromodeoxyuridine improves the cytotoxic effect of cisplatin: a comparison with 5-fluorouracil. Dr. Anibal Drelichman accepts Medicare.
Publications
- LeiomyoSarcoma of scrotum--case report and review of literature.
- Bromodeoxyuridine improves the cytotoxic effect of cisplatin: a comparison with 5-fluorouracil.
- Carcinoma of prostate metastatic to Breast.
- cis-platinum and 5-fluorouracil as initial therapy in advanced epidermoid Cancers of the head and neck.
- Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell Carcinoma of the head and neck.
- M-AMSA in disseminated prostatic Carcinoma: a phase II study.
- Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m--anisidine (AMSA) in patients with advanced head and neck Cancers.
- Phase II study of hexamethylmelamine for disseminated prostatic Carcinoma.
- Chemotherapy for nasopharyngeal Carcinoma. A ten-year experience.
- Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell Carcinoma of the head and neck.
- Mitoguazone in advanced renal Carcinoma: a phase II trial of the Southwest Oncology Group.
- Mitoxantrone: modest activity in a phase II trial in advanced prostate Cancer.
- Hypercalcemia in head and neck Carcinoma. Incidence and prognosis.
- Phase II evaluation of aclacinomycin-A (NSC-208734) in adenoCarcinoma of the kidney.
- Computerized bone scan. A potentially useful technique to measure response in prostatic Carcinoma.
- A randomized trial of the combination of cis-platinum, oncovin and bleomycin (COB) versus methotrexate in patients with advanced squamous cell Carcinoma of the head an...
- The effects of cyclophosphamide, ketoconazole, aclacinomycin-A, methotrexate, and scheduled methotrexate-5-fluorouracil combination chemotherapy on the transplantable ...
- Evaluation of cyclophosphamide, adriamycin, and cis-platinum (CAP) in patients with disseminated prostatic Carcinoma. A phase II study.
- Effects of cyclophosphamide alone and scheduled methotrexate-5-fluorouracil combination chemotherapy on transplantable R-3327 prostatic adenoCarcinoma in F1 hybrid mal...
- Ureteral obstruction secondary to metastatic Breast carcinoma.
- Phase II study of nafoxidine in the therapy for advanced renal Carcinoma.
- Quality performance improvement with the implementation of standard chemotherapy order forms.
- Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate Cancer previously treated with taxanes.
Schools
Universidad Nacional De Asuncion Facultad De Ciencias Medicas
Wayne State University Affil Hospital
Wayne State University
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Care Network PCP Focus Network
- Group Employees PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Health Alliance
- Preferred PPO
- Choice Care PPO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Priority PPO
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
Wayne State University School of Medicine -
Universidad Nacional de Asuncion Faculty of Medicine
Hospital
-
St. John Hospital and Medical Center -
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1740222447 | |
| NPPES Provider LastName | DRELICHMAN | |
| NPPES Provider FirstName | ANIBAL | |
| NPPES Provider ZIPCode | 480753707 | |
| NPPES Provider State | MI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1080.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 128.0 | |
| Percent Opioid Claims | 11.85 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1740222447 |
| Last Name Of The Provider | DRELICHMAN |
| First Name Of The Provider | ANIBAL |
| View All |
Similar Doctors
|
|
Dr. Andrew A. Muskovitz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Kraut, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Patrick W. McLaughlin, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Rajendra K. Manam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Clarence B. Vaughn, MD
This Doctor is OpenDoctor Recommended.
|